Is Bicycle Therapeutics plc (BCYC) Overvalued?
We dive into why Bicycle Therapeutics plc (BCYC) could be considered overvalued on 2026-08-19, based on AAII’s Value Score and Grade.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Commentary & Analysis
Why Bicycle Therapeutics plc’s (BCYC) Stock Is Up 5.04%
As of Friday, August 07, Bicycle Therapeutics plc’s BCYC share price has surged by 5.04%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About Bicycle Therapeutics plc's Q3 Earnings
Bicycle Therapeutics plc's fiscal Q3 earnings report was released on Thursday, July 30. Let's dive in to see if (BCYC) missed or beat analyst's expectations.Jenna Brashear
3 Undervalued Biotechnology Stocks for Tuesday, July 21
Discover the top 3 undervalued Biotechnology stocks for Tuesday, July 21 based on AAII’s Stock Grades.Tudor Pop
3 Undervalued Biotechnology Stocks for Wednesday, June 17
Discover the top 3 undervalued Biotechnology stocks for Wednesday, June 17 based on AAII’s Stock Grades.Jenna Brashear
Financial Summary
| Share Statistics | BCYC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $296.8 | $286.3 | 31% |
|
| Shares Out (Mil) | 69.8 | 54.2 | 55% |
|
| Institutional Ownership | 96.7% | 92.8% | 71% |
|
| Float (Mil) | na | 39.7 | na |
|
| Beta | 1.53 | 0.94 | 84% |
|
| Avg Daily Volume (000s) | 333 | 534 | 51% |
|
| Price Change (52-week) |
(41.0%) | 58.7% | 18% |
|
| Growth | BCYC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 47.5% | 13.6% | 95% |
|
| Net Income (5yr) | (33.8%) | (10.1%) | 12% |
|
| EPS (5yr) | (3.5%) | 16.0% | 27 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (29.1%) | (15.6%) | 20% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.459) | ($2.454) | ($2.224) | |
| Month Ago EPS | ($0.493) | ($2.275) | ($2.202) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.499) | ($2.306) | ($2.134) | |
| Year/Year Chg | (36.3%) | (22.4%) | (23.4%) | |
| Financials | BCYC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $61 | $37 | 22% |
|
| Net Income (TTM) (Mil) | ($190) | ($43) | 7% |
|
| EPS (TTM) | ($2.738) | ($1.400) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($206) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($212) | $2 | 10% |
|
| Long-Term Debt (Q1) (Mil) | $14 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | ($204) | $160 | 0% |
|
| Valuation | BCYC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.58 | 2.77 | 10% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BCYC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (208.9%) | 64.2% | 1% |
|
| Net Margin | (311.1%) | (75.9%) | 3% |
|
| ROA | (26.5%) | (47.3%) | 18% |
|
| ROE | (32.3%) | (55.0%) | 19% |
|
| Liabilities to Assets | 15.9% | 29.6% | 10% |
|
| F-Score | 3 | 2 | 18% |
|
Bicycle Therapeutics plc did not pass any screens on 8/20/2026.
